A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

NCT01021761 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Cataracts

Interventions

DRUG: Ketorolac Tromethamine
DRUG: Bromfenac
DRUG: nepafenac

Sponsor

Frank A. Bucci, Jr., M.D.

Collaborators

[object Object]